Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
- 25 April 2009
- journal article
- review article
- Published by Elsevier BV in Drug Resistance Updates
- Vol. 12 (3), 74-80
- https://doi.org/10.1016/j.drup.2009.03.002
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potentialDrug Resistance Updates, 2009
- Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic NicheCancer Cell, 2009
- Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesisNature, 2008
- A role for VEGF as a negative regulator of pericyte function and vessel maturationNature, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- The role of hypoxia-inducible factors in tumorigenesisCell Death & Differentiation, 2008
- Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote MetastasisCancer Cell, 2008
- Molecular and cellular biomarkers for angiogenesis in clinical oncologyDrug Discovery Today, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007